Sera Prognostics (SERA) is trading down at $2.00 (-4.31%), as of the latest quote. It operates in the Health Care sector.
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $25.0K | $82.0K | $268.0K | $306.0K | $77.0K | $81.0K |
| Growth (year over year) | — | +228.0% | +226.8% | +14.2% | −74.8% | +5.2% |
| Gross profit | — | — | — | $96.0K | −$5.00K | −$83.0K |
| Gross margin | — | — | — | 31.4% | −6.5% | −102.5% |
| Operating income | −$18.0M | −$35.4M | −$45.7M | −$39.8M | −$36.6M | −$36.5M |
| Operating margin | −71884.0% | −43164.6% | −17034.3% | −13013.4% | −47577.9% | −45066.7% |
| Net income | −$19.8M | −$35.0M | −$44.2M | −$36.2M | −$32.9M | −$31.9M |
| Net margin | −79392.0% | −42693.9% | −16487.3% | −11843.8% | −42724.7% | −39417.3% |
| EPS (diluted) | −$12.76 | −$2.33 | −$1.43 | −$1.16 | −$0.99 | −$0.67 |
| Balance sheet | ||||||
| Cash and equivalents | $13.5M | $58.9M | $29.9M | $3.88M | $4.04M | $3.94M |
| Total assets | $14.8M | $147.0M | $116.3M | $95.4M | $72.6M | $101.9M |
| Total liabilities | $12.3M | $8.46M | $17.4M | $25.3M | $24.8M | $26.5M |
| Shareholders' equity | −$125.6M | $138.6M | $98.9M | $70.2M | $47.8M | $75.4M |
| Cash flow | ||||||
| Operating cash flow | −$16.9M | −$31.6M | −$34.6M | −$27.2M | −$14.2M | −$25.6M |
| Capital expenditure | $149.0K | $1.30M | $791.0K | $128.0K | $56.0K | $726.0K |
| Free cash flow | −$17.0M | −$32.9M | −$35.4M | −$27.3M | −$14.2M | −$26.3M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $29.0K | $24.0K | $38.0K | $17.0K | $16.0K | $10.0K | $14.0K | $30.0K |
| Growth (year over year) | −31.0% | −41.5% | — | −29.2% | −44.8% | −58.3% | −63.2% | +76.5% |
| Gross profit | $16.0K | −$8.00K | −$2.00K | −$24.0K | −$25.0K | −$32.0K | −$28.0K | −$20.0K |
| Gross margin | 55.2% | −33.3% | −5.3% | −141.2% | −156.3% | −320.0% | −200.0% | −66.7% |
| Operating income | −$8.86M | −$9.42M | −$9.25M | −$9.32M | −$8.98M | −$8.95M | −$9.36M | −$10.0M |
| Operating margin | −30558.6% | −39262.5% | −24342.1% | −54823.5% | −56125.0% | −89540.0% | −66857.1% | −33346.7% |
| Net income | −$7.92M | −$8.58M | −$8.19M | −$8.05M | −$7.81M | −$7.88M | −$8.40M | −$9.14M |
| Net margin | −27306.9% | −35745.8% | −21544.7% | −47329.4% | −48837.5% | −78810.0% | −59992.9% | −30463.3% |
| EPS (diluted) | −$0.24 | −$0.25 | −$0.20 | −$0.16 | −$0.16 | −$0.15 | −$0.17 | −$0.18 |
| Balance sheet | ||||||||
| Cash and equivalents | $2.68M | $4.04M | $5.23M | $5.02M | $4.08M | $3.94M | $4.17M | $4.40M |
| Total assets | $79.0M | $72.6M | $118.2M | $111.8M | $108.1M | $101.9M | $93.5M | $86.7M |
| Total liabilities | $24.4M | $24.8M | $23.4M | $23.6M | $25.9M | $26.5M | $25.9M | $27.4M |
| Shareholders' equity | $54.7M | $47.8M | $94.8M | $88.2M | $82.2M | $75.4M | $67.6M | $59.4M |
| Cash flow | ||||||||
| Operating cash flow | −$7.00M | −$6.26M | −$7.55M | −$5.47M | −$6.48M | −$6.12M | −$8.77M | −$6.31M |
| Capital expenditure | $26.0K | $8.00K | $3.00K | $281.0K | $112.0K | $330.0K | $8.00K | $16.0K |
| Free cash flow | −$7.02M | −$6.27M | −$7.56M | −$5.75M | −$6.59M | −$6.45M | −$8.78M | −$6.33M |
From Sera Prognostics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Sera Prognostics in our feed yet.